<DOC>
	<DOCNO>NCT03073018</DOCNO>
	<brief_summary>The Prevention Renal Vascular Endstage Disease Intervention Trial ( PREVEND IT ) design determine whether intervention angiotensin-converting enzyme ( ACE ) inhibitor fosinopril and/or hydroxymethylglutaryl coenzyme A reductase inhibitor pravastatin reduce cardiovascular renal event nonhypertensive , nonhypercholesterolemic subject microalbuminuria .</brief_summary>
	<brief_title>Prevention Renal Vascular Endstage Disease Intervention Trial</brief_title>
	<detailed_description>This study describe rationale , design , baseline characteristic trial determine whether treatment fosinopril 20 mg/day and/or pravastatin 40 mg/ day prevent cardiovascular renal disease nonhypertensive ( RR &lt; 160/100 mm Hg use antihypertensive medication ) nonhypercholesterolemic ( total cholesterol &lt; 8.0 &lt; 5.0 mmol/L case previous myocardial infarction use lipid lower medication ) men woman persistent microalbuminuria ( urinary albumin excretion &gt; 10 mg/L early morning spot urine 15 300 mg/24-hour least two 24-hour urine collection ) . The Prevention REnal Vascular ENdstage Disease Intervention Trial single-center , double-blind , randomize , placebo-controlled trial 2 x 2 factorial design . The 864 randomized subject monitor minimum 4 year maximum 5 year . The primary efficacy parameter define combined incidence all-cause mortality hospital admission document ( 1 ) nonfatal myocardial infarction , ( 2 ) myocardial ischemia , ( 3 ) heart failure , ( 4 ) peripheral vascular disease , ( 5 ) cerebrovascular accident and/or ( 6 ) end-stage renal disease .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Fosinopril</mesh_term>
	<criteria>Persistent microalbuminuria ( urinary albumin excretion &gt; 10mg/L early morning spot urine 15 300 mg/24 hour least two 24hour urine sample ) No hypertension ( RR &lt; 160/100 mm Hg , antihypertensive medication ) No hypercholesterolemia ( total cholesterol &lt; 8.0 &lt; 5.0 mmol/L case previous myocardial infarction use lipidlowering medication ) Creatinine clearance &gt; 60 % normal ageadjusted value Serum potassium &gt; 5.5 mmol/L History chronic liver disease Lactate dehydrogenase , aspartateamino transferase alanineamino transferase &gt; 3 time upper limit normal Use angiotensinconverting enzyme inhibitor angiotensin II receptor antagonist Use insulin Previously document allergy intolerance study drug Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>